Table 1. Clinical characteristics of... | American Society of Hematology

Table 1.

Clinical characteristics of HIV-infected patients included in the study^*

Patients	Nontreated	Bi-RTI	HAART
No.	11	20	11
Age (y)	35.5 ± 9.2	40.2 ± 9.4	39.2 ± 8.5
Male/female	10/1	18/2	10/1
CD4 T lymphocytes (n/μL)	690.3 ± 303.2	595.2 ± 237.7	362.2 ± 217.4^†
Range	226-1281	233-1200	2-777
CD8 T lymphocytes (n/μL)	1102.1 ± 329.8	1039.7 ± 376.9	865.5 ± 435.0
Range	378-1698	434-1657	325-1597
CD4/CD8 ratio	0.78 ± 0.81	0.62 ± 0.29	0.41 ± 0.21^‡
Range	0.19-3.39	0.28-1.39	0.02-0.74
HIV RNA (copies/mL)^1-153	54 409 ± 95 491.3	3971 ± 6015	22 900.8 ± 60 920.4
Range	50-337 810	50-20 500	50-214 800
% of patients with viral load < 50 cp/mL	8	10	50
Antiretroviral therapy^1-155	None	2 RTIs	2 RTIs + 1 PI

Patients	Nontreated	Bi-RTI	HAART
No.	11	20	11
Age (y)	35.5 ± 9.2	40.2 ± 9.4	39.2 ± 8.5
Male/female	10/1	18/2	10/1
CD4 T lymphocytes (n/μL)	690.3 ± 303.2	595.2 ± 237.7	362.2 ± 217.4^†
Range	226-1281	233-1200	2-777
CD8 T lymphocytes (n/μL)	1102.1 ± 329.8	1039.7 ± 376.9	865.5 ± 435.0
Range	378-1698	434-1657	325-1597
CD4/CD8 ratio	0.78 ± 0.81	0.62 ± 0.29	0.41 ± 0.21^‡
Range	0.19-3.39	0.28-1.39	0.02-0.74
HIV RNA (copies/mL)^1-153	54 409 ± 95 491.3	3971 ± 6015	22 900.8 ± 60 920.4
Range	50-337 810	50-20 500	50-214 800
% of patients with viral load < 50 cp/mL	8	10	50
Antiretroviral therapy^1-155	None	2 RTIs	2 RTIs + 1 PI

Five patients in the bi-RTIs group had a nonnucleoside analogue: nevirapine or efavirenz. HIV protease inhibitors (PI) were indinavir or nelfinavir.

All data represent mean value ± SD. Statistical comparisons were made with the Mann-Whitney test.

P < .007 versus nontreated andP < .005 versus bi-RTI.

P < .05 versus bi-RTI.

Viral load was measured by the b-DNA assay (Chiron).P < .05 for bi-RTI versus nontreated.

Reverse transcriptase inhibitors (RTIs) were zidovudine, lamivudine, stavudine, didanosine, or abacavir.